Authors
Latest:
Sustained drug delivery in ophthalmologyCurrent options, challenges in developing novel therapies.
Latest:
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic AtrophyA retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
Latest:
ARVO 2025: Carl Danzig, MD, recaps the first stage of a phase 3 study of drop-based DME therapyAccording to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.
Latest:
Impact of Durable Therapies on Patients and Clinics and Monitoring StrategiesPanelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Latest:
FDA issues CRL for aflibercept 8 mg from Regeneron PharmaceuticalsThe company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Latest:
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal DiseasesPanelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Latest:
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMDDr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Latest:
UNCOVERING HIDDEN PREDATORS IN DISEASEThis article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Latest:
Natural language processing helps ophthalmologists access data, improves data curationKnowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
Latest:
Latest tech trends to benefit patients with AMDTechnology brings new tools to those with low vision caused by AMD
Latest:
Overcoming the wet AMD treatment gapA key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.
Latest:
Successful ocular surgery in patients with chronic uveitisWhile operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Latest:
Enhanced OCT GA segmentation achieved with new multistage modelResearchers introduce a multistage dual-branch network to improve accuracy and efficiency.
Latest:
Promoting Treatment Adherence in nAMD and DMEExperts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.
Latest:
Is complement therapy the path forward for geographic atrophy?Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
Latest:
Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidatesBoehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.
Latest:
Adapting medical retina service in COVID-19 era requires careful approachMinimizing clinic visits, maximizing use of imaging modalities are key
Latest:
ABVC BioPharma announces approved plan for pilot Good Manufacturing Practice (GMP) facility to produce VitargusThe plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
Latest:
Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresisNonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Latest:
New guidelines boost choriocapillaris imaging in AMD with SS-OCTACompensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
Latest:
New research raises questions about the current clinical approach to inherited retinal diseasesAlfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.
Latest:
Expert Insights: Ramiro Ribeiro, MD, PhD, discusses next steps in EYP-1901 researchRamiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.
Latest:
Ultra-widefield imaging: A critical step in uveitis diagnosis and managementA multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Latest:
Q&A: The increasing potential of ERG in diagnosing a wide range of eye conditionsEasier, more accessible functional studies have been made possible
Latest:
Geographic atrophy treatment: High attrition rates challenge long-term patient adherenceTwo FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.
Latest:
Humanity + technology: Talking to patients about the science and benefits of clinical trialsWhen we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
